CoDiagnostics (CODX)
(Delayed Data from NSDQ)
$1.25 USD
+0.03 (2.46%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.24 -0.01 (-0.80%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.25 USD
+0.03 (2.46%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.24 -0.01 (-0.80%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Alignment HealthCare Partners With Intermountain Health in Nevada
by Zacks Equity Research
ALHC partners with Intermountain Health to enhance access to high-quality care for Medicare members in Clark and Washoe counties, starting Jan 2025.
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
by Zacks Equity Research
Here is how Context Therapeutics Inc. (CNTX) and Co-Diagnostics, Inc. (CODX) have performed compared to their sector so far this year.
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CoDiagnostics (CODX) delivered earnings and revenue surprises of 26.47% and 564.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
GeneDx Holdings Corp. (WGS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 57.69% and 19.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 1.63% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Elevance Health (ELV) Beats Q1 Earnings Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 0.95% and 0.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.58% and 0.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -29.17% and 73.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sharecare, Inc. (SHCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sharecare, Inc. (SHCR) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of 13.04% and 45.27%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -57.14% and 3.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ModivCare (MODV) Misses Q1 Earnings Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -4.05% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
DocGo Inc. (DCGO) delivered earnings and revenue surprises of 120% and 4.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CoDiagnostics, Inc. (CODX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 33.33% and 24.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CoDiagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -166.67% and 75.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CoDiagnostics, Inc. (CODX) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Do Options Traders Know Something About CoDiagnostics (CODX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to CoDiagnostics (CODX) stock based on the movements in the options market lately.
CoDiagnostics, Inc. (CODX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 44.44% and 6.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Why the Earnings Surprise Streak Could Continue for CoDiagnostics, Inc. (CODX)
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CoDiagnostics, Inc. (CODX) Q4 Earnings Beat Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 66.67% and 5.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Q4 Earnings Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -4.76% and 2.02%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Biodesix, Inc. (BDSX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 2% and 1.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?